Efficacy of Methotrexate in Myasthenia Gravis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature. The specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are prednisone dependent. Patients will be randomized to receive either methotrexate or placebo and those who are entered onto this trial will have symptoms and signs of the disease while on prednisone therapy. The hypothesis is that adding methotrexate therapy in these patients will improve the MG manifestations so that the prednisone dose can be reduced and clinical measures of MG severity will improve.
| Condition | Intervention | Phase |
|---|---|---|
|
Myasthenia Gravis |
Drug: Methotrexate Other: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Phase II Trial of Methotrexate in Myasthenia Gravis |
- Total prednisone dose [ Time Frame: 9 months ] [ Designated as safety issue: No ]
- Quantitative Myasthenia Gravis score [ Time Frame: baseline, monthly for 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Methotrexate
|
Drug: Methotrexate
10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
|
|
Placebo Comparator: 2
Placebo
|
Other: Placebo
Weekly
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have MGFA MG grades 2, 3, or 4 generalized myasthenia gravis, according to the MGFA classification system
- Elevated acetylcholine receptor antibody (AChR-Ab) titer.
- Patient's signs and symptoms should not be better explained by another disease process.
- Prednisone dose of at least 10 mg/day (or the equivalent in alternate days) and the subject must be on a stable dose of prednisone for 30 days prior to the screening visit.
Exclusion Criteria:
- A history of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue.
- Other major chronic or debilitating illnesses within six months prior to study entry.
- Female patients who are premenopausal and are: (a) pregnant on the basis of a serum pregnancy test, (b) breast-feeding, or (c) not using an effective method of double barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth control (birth control pills, male condom, female condom, intrauterine device, Norplant, tubal ligation, or other sterilization procedures).
- Altered levels of consciousness, dementia, or abnormal mental status.
- Evidence of thymoma on chest CT or MRI. Such a finding could require immediate thymectomy and would preclude entry into the study.
- Thymectomy in the previous three months.
- Patients who have been medicated with azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, IVIg, or other immunosuppressive drugs within the last 60 days.
- Chest X-ray with evidence of tumor, infection, or interstitial lung disease.
- Clinical history of chronic or recurrent infections.
- Daily use of non-steroidal anti-inflammatory drugs (NSAIDs).
- History of renal or hepatic insufficiency or liver enzymes greater than the upper limit of normal.
- History of bone marrow hypoplasia, leucopenia, thrombocytopenia, significant anemia, clinical or laboratory evidence of immunodeficiency syndromes.
- Forced Vital Capacity (FVC) <50% of predicted.
- MG Grade 1 (ocular only) or 5 (crisis, requiring ventilator).
- Prior use of methotrexate for any condition.
Contacts and Locations| United States, Arizona | |
| Phoenix Neurological Associates | |
| Phoenix, Arizona, United States, 85018 | |
| United States, California | |
| University of California, San Francisco | |
| Fresno, California, United States, 93701 | |
| University of California-Irvine | |
| Irvine, California, United States, 92697 | |
| Forbes Norris MDA/ALS Research Center | |
| San Francisco, California, United States, 94115 | |
| United States, Florida | |
| University of Miami | |
| Coral Gabel, Florida, United States, 33124 | |
| University of Florida, Health Science Center Jacksonville | |
| Jacksonville, Florida, United States, 32209 | |
| United States, Indiana | |
| Indiana University | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Iowa | |
| University of Iowa Hospitals and Clinics | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Massachusetts | |
| Massachusetts General Hospitals | |
| Boston, Massachusetts, United States, 02114 | |
| United States, North Carolina | |
| University of North Carolina | |
| Chapel Hill, North Carolina, United States, 27599 | |
| United States, Ohio | |
| Ohio State University | |
| Columbus, Ohio, United States, 43210 | |
| United States, Pennsylvania | |
| Penn State College of Medicine, The Milton S. Hershey Medical Center | |
| Hershey, Pennsylvania, United States, 17033 | |
| United States, Texas | |
| University of Texas Southwestern Medical Center | |
| Dallas, Texas, United States, 75390 | |
| The Nerve and Muscle Center of Texas | |
| Houston, Texas, United States, 77030 | |
| Methodist Hospital System | |
| Houston, Texas, United States, 77030 | |
| University Health Sciences Center, San Antonio | |
| San Antonio, Texas, United States, 78229 | |
| United States, Virginia | |
| University of Virginia | |
| Charlottesville, Virginia, United States, 22908 | |
| Canada, Ontario | |
| University of Toronto | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Canada, Quebec | |
| Montreal Neurological Institute and Hospital | |
| Montreal, Quebec, Canada, H3A 2B4 | |
| Principal Investigator: | Richard Barohn, MD | University of Kansas |
More Information
No publications provided
| Responsible Party: | Richard Barohn, MD, Gertrude and Dewey Zeigler Professor of Neurology, Chairman Deptartment of Neurology, University of Kansas |
| ClinicalTrials.gov Identifier: | NCT00814138 History of Changes |
| Other Study ID Numbers: | 11552 |
| Study First Received: | December 23, 2008 |
| Last Updated: | February 19, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Kansas:
|
myasthenia gravis |
Additional relevant MeSH terms:
|
Myasthenia Gravis Muscle Weakness Autoimmune Diseases of the Nervous System Nervous System Diseases Neuromuscular Junction Diseases Neuromuscular Diseases Autoimmune Diseases Immune System Diseases Muscular Diseases Musculoskeletal Diseases Neuromuscular Manifestations Neurologic Manifestations Pathologic Processes Signs and Symptoms Methotrexate |
Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors |
ClinicalTrials.gov processed this record on May 21, 2013